Page 137 - 《中国药房》2024年5期

Biol，2017，1652：3-35. HER2-positive metastatic breast cancer （PHOEBE）：a
[ 6 ] CHOONG G M，CULLEN G D，O’SULLIVAN C C. multicentre，open-label，randomised，controlled，phase 3
Evolving standards of care and new challenges in the trial[J]. Lancet Oncol，2021，22（3）：351-360.
management of HER2-positive breast cancer[J]. CA Cancer [17] MA F，YAN M，LI W，et al. Pyrotinib versus placebo in
J Clin，2020，70（5）：355-374. combination with trastuzumab and docetaxel as first line
[ 7 ] JUNTTILA T T，AKITA R W，PARSONS K，et al. Ligand- treatment in patients with HER2 positive metastatic breast
independent HER2/HER3/PI3K complex is disrupted by cancer （PHILA）：randomised，double blind，multicentre，
trastuzumab and is effectively inhibited by the PI3K in‐ phase 3 trial[J]. BMJ，2023，383：e076065.
hibitor GDC-0941[J]. Cancer Cell，2009，15（5）：429-440. [18] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会
[ 8 ] TRIANTAFYLLIDI E，TRIANTAFILLIDIS J K. Syste- （CSCO）乳腺癌诊疗指南：2023[M].北京：人民卫生出版
matic review on the use of biosimilars of trastuzumab in 社，2023：27，85.
HER2+ breast cancer[J]. Biomedicines，2022，10（8）： Guidelines Working Committee of Chinese Society of
2045. Clinical Oncology. Guidelines for breast cancer diagnosis
[ 9 ] NIELSEN D L，ANDERSSON M，KAMBY C. HER2-tar‐ and treatment of Chinese Society of Clinical Oncology
geted therapy in breast cancer. Monoclonal antibodies and （CSCO）：2023[M]. Beijing：People’s Health Publishing
tyrosine kinase inhibitors[J]. Cancer Treat Rev，2009，35 House，2023：27，85.
（2）：121-136. [19] GIANNI L，EIERMANN W，SEMIGLAZOV V，et al.
[10] SLAMON D J，LEYLAND-JONES B，SHAK S，et al. Neoadjuvant chemotherapy with trastuzumab followed by
Use of chemotherapy plus a monoclonal antibody against adjuvant trastuzumab versus neoadjuvant chemotherapy
HER2 for metastatic breast cancer that over expresses alone，in patients with HER2-positive locally advanced
HER2[J]. N Engl J Med，2001，344（11）：783-792. breast cancer （the NOAH trial）：a randomised controlled
[11] MARTY M，COGNETTI F，MARANINCHI D，et al. Ran‐ superiority trial with a parallel HER2-negative cohort[J].
domized phase Ⅱ trial of the efficacy and safety of trastu‐ Lancet，2010，375（9712）：377-384.
zumab combined with docetaxel in patients with human [20] GIANNI L，EIERMANN W，SEMIGLAZOV V，et al.
epidermal growth factor receptor 2-positive metastatic Neoadjuvant and adjuvant trastuzumab in patients with
breast cancer administered as first-line treatment：the HER2-positive locally advanced breast cancer （NOAH）：
M77001 study group[J]. J Clin Oncol，2005，23（19）： follow-up of a randomised controlled superiority trial with
4265-4274. a parallel HER2-negative cohort[J]. Lancet Oncol，2014，
[12] RICHARD S，SELLE F，LOTZ J P，et al. Pertuzumab and 15（6）：640-647.
trastuzumab：the rationale way to synergy[J]. An Acad [21] GIANNI L，PIENKOWSKI T，IM Y H，et al. Efficacy and
Bras Cienc，2016，88（Suppl 1）：565-577. safety of neoadjuvant pertuzumab and trastuzumab in
[13] SWAIN S M，MILES D，KIM S B，et al. Pertuzumab， women with locally advanced，inflammatory，or early
trastuzumab，and docetaxel for HER2-positive metastatic HER2-positive breast cancer （NeoSphere）：a randomised
breast cancer （CLEOPATRA）：end-of-study results from multicentre，open-label，phase 2 trial[J]. Lancet Oncol，
a double-blind，randomised，placebo-controlled，phase 3 2012，13（1）：25-32.
study[J]. Lancet Oncol，2020，21（4）：519-530. [22] GIANNI L，PIENKOWSKI T，IM Y H，et al. 5-year analy‐
[14] XU B H，LI W，ZHANG Q Y，et al. Pertuzumab，trastu‐ sis of neoadjuvant pertuzumab and trastuzumab in patients
zumab，and docetaxel for Chinese patients with previously with locally advanced，inflammatory，or early-stage
untreated HER2-positive locally recurrent or metastatic HER2-positive breast cancer （NeoSphere）：a multicentre，
breast cancer （PUFFIN）：a phase Ⅲ，randomized，double- open-label，phase 2 randomised trial[J]. Lancet Oncol，
blind，placebo-controlled study[J]. Breast Cancer Res 2016，17（6）：791-800.
Treat，2020，182（3）：689-697. [23] SHAO Z M，PANG D，YANG H J，et al. Efficacy，safety，
[15] MILES D，CIRUELOS E，SCHNEEWEISS A，et al. Final and tolerability of pertuzumab， trastuzumab， and
results from the PERUSE study of first-line pertuzumab docetaxel for patients with early or locally advanced
plus trastuzumab plus a taxane for HER2-positive locally ERBB2-positive breast cancer in Asia：the PEONY phase
recurrent or metastatic breast cancer，with a multivariable 3 randomized clinical trial[J]. JAMA Oncol，2020，6（3）：
approach to guide prognostication[J]. Ann Oncol，2021，32 e193692.
（10）：1245-1255. [24] SHAO Z M，PANG D，YANG H J，et al. Abstract PD18-03：
[16] XU B H，YAN M，MA F，et al. Pyrotinib plus capecitabine final analysis of the phase Ⅲ PEONY trial：long-term
versus lapatinib plus capecitabine for the treatment of efficacy and safety of neoadjuvant-adjuvant pertuzumab

中国药房 2024年第35卷第5期 China Pharmacy 2024 Vol. 35 No. 5 · 639 ·